Viemed Healthcare Inc (VMD) Q1 2026 Earnings Call Transcript

Why It Matters

The results demonstrate Viemed’s ability to grow organically while diversifying into higher‑margin, capital‑light services, positioning it for sustained profitability and market share gains in the evolving home‑health landscape.

Key Takeaways

• Revenue increased 14.7% YoY, driven entirely by organic growth
• Sleep therapy patients rose 15% sequentially, fastest‑growing segment
• Lehan’s acquisition adds maternal health, expands Illinois/Wisconsin footprint
• Adjusted EBITDA grew 12% YoY to $14.3 million, margin 22.7%
• Share buyback repurchased 270k shares for $1.8 million, no net debt

Pulse Analysis

Viemed Healthcare’s second‑quarter 2025 earnings underscore the resilience of the home‑based respiratory market. The company posted a 14.7% year‑over‑year revenue increase with every increment coming from organic expansion, a rare feat in a sector often buoyed by acquisitions. Core in‑home ventilation, which still represents more than half of sales, delivered a solid 5% sequential rise, confirming the firm’s continued leadership in non‑invasive ventilation. This steady top‑line momentum reflects both a growing elderly population requiring chronic respiratory support and Viemed’s deep payer relationships that facilitate consistent patient enrollment.

The quarter also highlighted the company’s strategic shift toward higher‑margin, capital‑light services. Sleep therapy patient counts jumped 15% sequentially and new sleep setups surged 72% year‑over‑year, propelling the segment to roughly one‑fifth of total revenue. The resupply program, now up 10% sequentially, further leverages Viemed’s logistics platform to generate recurring cash flow. Complementing organic growth, the July acquisition of Lehan’s Medical Equipment expands the product mix into maternal health and deepens distribution in Illinois and Wisconsin, broadening the addressable market and cross‑selling opportunities across the respiratory and sleep portfolios.

Financially, Viemed entered the quarter with a strong balance sheet—$20 million cash, $55 million of available credit and no net debt—allowing it to fund a 5% share‑repurchase program and the $27 million Lehan’s deal without diluting shareholders. Adjusted EBITDA rose 12% YoY to $14.3 million, while SG&A fell to 45.7% of revenue, indicating operating leverage from the evolving mix. Management raised full‑year guidance to $271‑$277 million in revenue and $59‑$62 million EBITDA, buoyed by the NCD final rule that eases step‑therapy constraints and positions Viemed to capture additional Medicare volume ahead of any future competitive bidding cycles.